Turn Therapeutics Inc.

NASDAQ:TTRX

Biotechnology

Healthcare
$8.89 -2.79%

-$0.17 today

Market cap
$271.79M
Beta
2.77
P/E (TTM)
-45.0
EPS (TTM)
-$0.13
52W Low $2.57High $26.50

Volume 0.05M

Average 0.04M

TTRX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Turn Therapeutics Inc.NASDAQ: TTRX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development of $109.43K in Q1 FY2026

Q1 FY2026 research & development was $109.43K. Trailing-twelve-month research & development was $365.75K.

Context

  • Research & development increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly research & development holds near $109.43K or moves back toward the trailing-twelve-month quarterly average of $91.44K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$109.43K+213.3% QoQ
Last fiscal yearDec 2025
$265.57K+8.0% YoY
LTMMar 2026
$365.75K— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+8.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
265.57K USD
Year-over-year change
+8.0%
2-year CAGR
+495.1%

Research & Development vs competitors

How TTRX compares with its peers on the latest reported figures

  • TTRX's LTM Mar 2026 research & development of $365.75K is the lowest of the 9 companies compared; the peer median is $31.29M.
TTRX Competitors Peer median
Research & Development for TTRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SEERSeer, Inc.LTM Mar 2026$41.33M -11.2%-6.2%274.8%
AGENAgenus Inc.LTM Mar 2026$38.53M -58.1%—31.1%
IRDOpus Genetics, Inc.LTM Mar 2026$33.44M +11.2%+29.0%279.0%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$32.45M -22.6%+7.0%—
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$30.12M +20.6%+35.3%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$21.18M +82.5%+30.2%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$15.76M +21.0%+38.5%—
ANIXAnixa Biosciences, Inc.LTM Apr 2026$4.56M -27.4%-8.9%—
TTRXTurn Therapeutics Inc.LTM Mar 2026$365.75K ———
Peer median (excluding TTRX) $31.29M+0.0%+29.0%274.8%

Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue000
Gross Profit000
Gross Margin———
Research & Development7.5K245.96K265.57K
Selling, General & Admin2.3M1.55M5.59M
Operating Expenses2.31M1.8M5.86M
Depreciation & Amortization43.92K47.48K52.75K
EBITDA(2.25M)(1.72M)(3.14M)
EBITDA Margin———
Operating Income(2.31M)(1.8M)(5.86M)
Operating Margin———
Interest Income15.88K28.71K29.58K
Interest Expense000
Other Income / Expenses15.88K28.71K2.66M
Income Before Tax(2.29M)(1.77M)(3.19M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(2.29M)(1.77M)(3.19M)
Net Margin———
EPS (Basic)(0.17)(0.13)(0.23)
EPS (Diluted)(0.17)(0.13)(0.23)
Weighted Avg Shares13.25M13.42M13.74M
Weighted Avg Shares (Diluted)13.25M13.42M13.74M

Turn Therapeutics Inc.

NASDAQ:TTRX

Intrinsic Alpha fair value

Locked

Current Price

$8.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.